Eywa Biotech raises $2.5M for psychedelic compounds

It all started one night when I woke up with the realization that we needed to establish a partnership with the Reprogramming Lab, a cutting‑edge stealth biotech startup. The potential of combining interventions that both reverse and slow aging is too important to leave unexplored. This path is also fully aligned with the Rapamycin Longevity Lab’s roadmap of pushing the boundaries of human longevity and moving closer to radical life extension. The plan was to explore this type of combination further in the future but when such a remarkable opportunity arose with a great startup and the talented team behind it I knew this was something we needed to do now. We are therefore moving forward with a combination of pharmaceutical partial reprogramming, aimed at reversing cellular age, and an mTOR inhibitor, recognized as the gold standard for slowing aging across multiple species. By bringing these two together our goal is to see if their longevity effects can be amplified. To explore this we will use the pioneering Pump Science platform to fund and accelerate the research and generate unique data in worms, flies and mice as the initial milestone. This is an important step forward where reverse and slow down aging interventions are united with the purpose to move closer to radical life extension!

Our latest TechBio report spotlights how UK innovators are securing major rounds demonstrating market maturity and global investor confidence in data-driven biology. ➡️ Isomorphic Labs (BIA member) – raised £448.9 million inEurope’s largest-ever AI fundraise (series A) . This Alphabet-incubated powerhouse is reimagining drug discovery through advanced AI models. ➡️ CHARM Therapeutics (BIA member) – raised $80 million (£59.4 million) in a Series B to accelerate its clinical pipeline, using proprietary AI algorithms inspired by protein-folding pioneer David Baker. ➡️ Lindus Health – closed a £44.6 million Series B, advancing AI-driven platform to streamline clinical trial design, from recruitment to execution — making studies faster and more efficient. Together, these companies show how UK TechBio is moving from promise to presence - scaling world-class science into global impact.   Read the full report to see the data behind the momentum: https://techbio.org.uk/ #TechBioUK #TechBio #Biotech 

Thrilled to to be an early backer of Adaptyx Biosciences, who came out of stealth today with a $14M seed to build continuous, multi-analyte molecular monitoring at scale. 🔬⚡ As a long-time researcher and company builder in diagnostics & preventive medicine, I’ve watched the science of predictive biomarkers explode, yet translation has lagged. Why? Because it’s brutally hard to (1) measure the right molecules cost-effectively at scale, and (2) track dynamic changes over time to deliver truly actionable insights. A “CGM for everything” is the holy grail. The medical tricorder. The company that cracks this will become a $100B backbone for tomorrow's healthcare. The hardest problems are obvious: - Technical complexity: reliable, multi-analyte sensing in a CGM form factor requires world class biochemistry, materials science, optics, electronics, and AI. Hardware is hard, and bio is harder. - Regulatory & payer pathways: this is the real killer of biomarker innovation. It took CGM decades to navigate the regulatory and payment landscape. - Scalable solutions to reach the consumer market: The future is an AI in your pocket, tracking your biology and keeping you healthy and out of the doctor's office. We need a solution that can scale to everyone. I did a deep dive on the tech tree last year and was convinced all the raw ingredients existed. I almost set off to build this myself… then I met Adaptyx. They were already building it—world-class talent, science, and execution—so we chose to back them instead. We’re proud to support the seed round at Starbloom Capital, alongside great partners like Interlagos, Overwater Ventures, Stanford University, and Chan Zuckerberg Initiative If you care about the future of continuous health and biomarker intelligence, keep an eye on Adaptyx. This is one of those rare platforms with the potential to reset the category. https://lnkd.in/gnA_tw7Z

Predicta Biosciences secures an impressive $23.4M funding round led by Engine Ventures, accelerating its mission to revolutionize precision healthcare through AI-driven biological insights. This investment marks a pivotal step toward advancing predictive diagnostics and personalized medicine, setting new standards in the biotech landscape. The future of bioscience innovation looks brighter than ever. #BiotechInnovation #FundingNews #AIinHealthcare #PredictiveMedicine #StartupGrowth CCI India (Chamber of Commerce & Industry of India) Looking forward to raise funds . Kindly follow us. Send pitch deck on secretariat@cciindia.org Munindra kumar

Cambridge’s biotech engine keeps moving. Labiotech.eu spoke with Dr Ola (Aleksandra) Wlodek, CEO of Constructive Bio, about what makes the cluster work. She highlights the mix of science, talent, and a connected investor base — and kindly mentions Amadeus. What the piece covers: • Why Cambridge stands out: world-class research, strong founders, and global pharma on the doorstep (including Illumina’s roots in the city). • Big commitments: BioNTech plans up to £1bn for UK R&D over 10 years, including a new Cambridge centre. • Funding momentum: $1.34bn raised by Cambridge life sciences in the 12 months to mid-Oct 2024; Q1 2025 saw $198m across eight deals. • The pipeline: a new wave of spinouts and scaleups, with investors like Amadeus supporting growth. Read the article: https://lnkd.in/eKUuV5Ca

At the NY #LifeScienceSummit 2025 closing plenary session yesterday, MEC Managing Partner Kim Kamdar, PhD, moderated an investor roundtable featuring: • Sonia Gulati, PhD, Global BioAccess Fund • Eric Heil, MBA, Medical Excellence Capital • Jonathan Mandelbaum, PhD, OrbiMed • Megan Blewett, Scion Life Sciences The discussion explored how investors and entrepreneurs are balancing scientific ambition with financial discipline in the current fundraising climate. “The market has moved from rewarding optionality to rewarding focus. You can be ambitious scientifically, but you have to be disciplined financially.” Panelists shared perspectives on early-stage company building, emphasizing the importance of strong mentors, Executive Chairs, and the concept of matching leadership–market fit alongside traditional product–market fit. The group also discussed exciting areas of investor enthusiasm, including CNS, cell therapy, RNA, oligonucleotide therapeutics, and novel chemistry platforms that could one day rival or replace monoclonal antibodies. The conversation then turned global, touching on the opportunities and risks of engaging with China’s biotech ecosystem. The panel reflected on how capital flows are shaping the competitive landscape and the long-term implications for global innovation and market dynamics. With a note of caution, Eric commented: “Yes, right now China may be faster and cheaper today, but with all the capital flowing into China, we may be a bit short sighted and we must realize that we are financing Chinese biotech global aspirations and capabilities—are we ready for global Chinese pharma brands competing worldwide, undercutting U.S. innovation and global pharmaceutical companies?” Think: examples from other industries (e.g. manufacturing, tech, etc.) The session concluded on a note of optimism: biotech sentiment is improving, with brighter markets expected into 2026. As one panelist put it, “there’s a lot more green on the stock screen these days.” And it closed with a short poem from Eric: “Let it be in ’23, More in ’24, Survive through ’25, Fixed in ’26, Heaven in ’27.” #LifeSciences #Biotech #VentureCapital #Innovation #Resilience #MedicalExcellenceCapital

A very nice compilation along with observations and recommendations on Creating products/solutions from Research. IIITH is one of the 6 institutions studied (others being IISc, IITD, IITB, BITS and CCAMP).

Thoughts on Sirtris from this morning's Norn Group discussion: ICYMI: Sirtris = high-profile longevity company based on resveratrol in early 2000s. Sold to GSK for $720M, went nowhere, controversy about scientific robustness. But it's not really a story about #longevity. Important points: - The CEO Christoph Westphal was very hot stuff. Previously founded Momenta ($6B acq), Acceleron ($11B acq), and Alnylam Pharmaceuticals. - It all went down in a boom period before 2008 crash: IPO was early 2007, acq early 2008. - From filings, it seems that GSK was not putting much stock in Sirtris' lead compound (reformulated resveratrol). So maybe they bought into the vision and didn't mind the experimental issues because they always planned to start over. - Pharmas are going to do M&A. If it's a bull market there are fewer/worse options. Realistically, the alternative to Sirtris was some other company with blockbuster potential, not sitting on cash. CEO with track record partners with high-profile academic for new thing that could be huge. Pitch investors in bull market: If we wait for replication we'll miss out! Full speed ahead with a solid strategy for hitting a large market, with key timing of publications and news to keep hype going. Whether the science is sirtuins, CAR-T, circular RNAs, or CRISPR, this story happened before and happens today. Sometimes it works, sometimes it fails, sometimes another company ends up succeeding with more mature version of the science. You can see that it's not a unique story in the aftermath: careers didn't end, the people involved went on to do more companies. The fact that Sirtris was based on longevity gets more attention because 1) longevity field has more pseudoscience than most so failure fits narrative, 2) longevity field doesn't have many large companies, so what happens to one of them gets attention. The science did not work, the hype did, and there aren't too many lessons on longevity to be learned. The field will keep trying new ideas, and when there's a success or two things will get very exciting.

For some strange reason (irony intended), we don’t get much training during neurosurgery residency or clinical practice towards the business side of running a neurotechnology startup. As a result, I’ve managed to experience all the challenges outlined in the “founder handbook” - picture the Blade Runner robot running in slow motion through a series of plate-glass windows. With many thanks to the visionary teams at KdT Ventures and PsyMed Ventures, very much looking forward to sharing some of these experiences and the associated on-the-ground insights during the Future Neuro Founders Program series on October 10th. https://lnkd.in/e-bRrehs #KdTVentures #PsyMedVentures #Neurotechnology #BrainMonitoring #AIinMedicine #Innovation

CHF 40,000 for Dexterous Endoscopes, Latentfusion.ai, and LightSeeds. These three projects were selected at Venture Kick's second financial and entrepreneurial support stage. 💰 https://lnkd.in/dp-5UPr9 Meet the three successful projects: CTO Yi Sun & CEO Yegor Piskarev | Dexterous Endoscopes: Empowering doctors to achieve optimal patient outcomes. 🏥 https://lnkd.in/dn6tPsPY CEO Elias Hagmann & CSO Dieter Schiegg | Latentfusion.ai: Optimizing protein-based therapeutics to unlock innovative treatments. 🧬 https://lnkd.in/dEHyvZnN Co-founders Pierrick Duvoisin & Laure-Emmanuelle Perret | LightSeeds: Reducing solar installation costs with lightweight, low-carbon technology. ☀️ https://lnkd.in/df2Ns_jd #VentureKick #SwissStartups